Alzheon
Framingham, Massachusetts, United States · Biotechnology
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and
Key facts
- Headquarters
- Framingham, Massachusetts, United States
- Employees
- 31
- Industries
- Biotechnology
- Status
- Private
- Website
- alzheon.com
- Company page
Recent activity at Alzheon
- : ALZHEON
- : Alzheon, Inc. Appoints Muneer A. Satter to Board of Directors to Guide Upcoming Commercialization Efforts.
- : Alzheon, Inc. raised $100 million in Series E financing led by Alerce Medical Technology Partners to advance the development and commercialization of oral tablet ALZ-801/Valiltramiprosate for the treatment of Alzheimer’s disease.
- : ALZHEON
- : ALZHEON
- : ALZHEON
- : ALZHEON
- : Alzheon Announces Closing Of Oversubscribed $50 Million Series D Financing Round To Accelerate Completion Of Apolloe4 Phase 3 Trial And Expansion Of Product Portfolio
- : ALZHEON, INC.
- : ALZHEON, INC.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Alzheon funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Venture | $78.8M |
| Jun 2024 | Series E | $100.0M |
| Feb 2024 | Venture | $17.2M |
| Dec 2022 | Series D | $1.7M |
| Apr 2022 | Series D | $50.0M |
Leadership
- Martin Tolar, Director, Executive Officer
- Diane M.D., Director
- Noel Dunn, Director
- David Ph.D., Director
- Jordan Heller, Director
- Neil Flanzraich, Director
- Martin Ph.D., Director, Executive Officer
- Jean-Pierre Garnier, Director
- Dennis Langer, Director
- Franz Hefti, Director
Verified email and direct lines for Alzheon’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Alzheon files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Alzheon
- Actinium Pharmaceuticals · Biotechnology
- Cardiff Oncology · Biotechnology
- Saniona · Biotechnology
- Diden Robotics · Biotechnology
- Qilin Zhengwei · Biotechnology
About Alzheon: questions and answers
What does Alzheon do?
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and
Where is Alzheon headquartered?
Alzheon is headquartered in Framingham, Massachusetts, United States.
How many employees does Alzheon have?
Alzheon has about 31 employees.
Has Alzheon raised funding?
Yes. Fundz has recorded 5 funding events for Alzheon. The most recent, $78.8M, was in Aug 2026.
What is the latest news on Alzheon?
On Aug 26, 2026, ALZHEON
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy